Personal information

No personal information available

Activities

Collapse all

Employment (1)

Mass General Brigham: Boston, US

2022 to present | Research Assistant
Employment
Source: Self-asserted source
Phoebe Ryan

Works (25)

Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer

Clinical Cancer Research
2024-07-15 | Journal article
DOI: 10.1158/1078-0432.CCR-24-0428
Contributors: Aditya Bardia; Sheng Sun; Nayana Thimmiah; James T. Coates; Bogang Wu; Rachel O. Abelman; Laura Spring; Beverly Moy; Phoebe Ryan; Mark N. Melkonyan et al.
Source: check_circle
Crossref

Data from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer

2024-07-15 | Preprint
DOI: 10.1158/1078-0432.c.7348821
Contributors: Aditya Bardia; Sheng Sun; Nayana Thimmiah; James T. Coates; Bogang Wu; Rachel O. Abelman; Laura Spring; Beverly Moy; Phoebe Ryan; Mark N. Melkonyan et al.
Source: check_circle
Crossref

Data from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer

2024-07-15 | Preprint
DOI: 10.1158/1078-0432.c.7348821.v1
Contributors: Aditya Bardia; Sheng Sun; Nayana Thimmiah; James T. Coates; Bogang Wu; Rachel O. Abelman; Laura Spring; Beverly Moy; Phoebe Ryan; Mark N. Melkonyan et al.
Source: check_circle
Crossref

Supplementary Figure S1 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer

2024-07-15 | Preprint
DOI: 10.1158/1078-0432.26302824
Contributors: Aditya Bardia; Sheng Sun; Nayana Thimmiah; James T. Coates; Bogang Wu; Rachel O. Abelman; Laura Spring; Beverly Moy; Phoebe Ryan; Mark N. Melkonyan et al.
Source: check_circle
Crossref

Supplementary Figure S1 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer

2024-07-15 | Preprint
DOI: 10.1158/1078-0432.26302824.v1
Contributors: Aditya Bardia; Sheng Sun; Nayana Thimmiah; James T. Coates; Bogang Wu; Rachel O. Abelman; Laura Spring; Beverly Moy; Phoebe Ryan; Mark N. Melkonyan et al.
Source: check_circle
Crossref

Supplementary Figure S2 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer

2024-07-15 | Preprint
DOI: 10.1158/1078-0432.26302821.v1
Contributors: Aditya Bardia; Sheng Sun; Nayana Thimmiah; James T. Coates; Bogang Wu; Rachel O. Abelman; Laura Spring; Beverly Moy; Phoebe Ryan; Mark N. Melkonyan et al.
Source: check_circle
Crossref

Supplementary Figure S2 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer

2024-07-15 | Preprint
DOI: 10.1158/1078-0432.26302821
Contributors: Aditya Bardia; Sheng Sun; Nayana Thimmiah; James T. Coates; Bogang Wu; Rachel O. Abelman; Laura Spring; Beverly Moy; Phoebe Ryan; Mark N. Melkonyan et al.
Source: check_circle
Crossref

Supplementary Figure S3 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer

2024-07-15 | Preprint
DOI: 10.1158/1078-0432.26302818
Contributors: Aditya Bardia; Sheng Sun; Nayana Thimmiah; James T. Coates; Bogang Wu; Rachel O. Abelman; Laura Spring; Beverly Moy; Phoebe Ryan; Mark N. Melkonyan et al.
Source: check_circle
Crossref

Supplementary Figure S3 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer

2024-07-15 | Preprint
DOI: 10.1158/1078-0432.26302818.v1
Contributors: Aditya Bardia; Sheng Sun; Nayana Thimmiah; James T. Coates; Bogang Wu; Rachel O. Abelman; Laura Spring; Beverly Moy; Phoebe Ryan; Mark N. Melkonyan et al.
Source: check_circle
Crossref

Supplementary Figure S4 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer

2024-07-15 | Preprint
DOI: 10.1158/1078-0432.26302815.v1
Contributors: Aditya Bardia; Sheng Sun; Nayana Thimmiah; James T. Coates; Bogang Wu; Rachel O. Abelman; Laura Spring; Beverly Moy; Phoebe Ryan; Mark N. Melkonyan et al.
Source: check_circle
Crossref

Supplementary Figure S4 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer

2024-07-15 | Preprint
DOI: 10.1158/1078-0432.26302815
Contributors: Aditya Bardia; Sheng Sun; Nayana Thimmiah; James T. Coates; Bogang Wu; Rachel O. Abelman; Laura Spring; Beverly Moy; Phoebe Ryan; Mark N. Melkonyan et al.
Source: check_circle
Crossref

Supplementary Table S1 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer

2024-07-15 | Preprint
DOI: 10.1158/1078-0432.26302812
Contributors: Aditya Bardia; Sheng Sun; Nayana Thimmiah; James T. Coates; Bogang Wu; Rachel O. Abelman; Laura Spring; Beverly Moy; Phoebe Ryan; Mark N. Melkonyan et al.
Source: check_circle
Crossref

Supplementary Table S1 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer

2024-07-15 | Preprint
DOI: 10.1158/1078-0432.26302812.v1
Contributors: Aditya Bardia; Sheng Sun; Nayana Thimmiah; James T. Coates; Bogang Wu; Rachel O. Abelman; Laura Spring; Beverly Moy; Phoebe Ryan; Mark N. Melkonyan et al.
Source: check_circle
Crossref

Supplementary Table S2 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer

2024-07-15 | Preprint
DOI: 10.1158/1078-0432.26302806
Contributors: Aditya Bardia; Sheng Sun; Nayana Thimmiah; James T. Coates; Bogang Wu; Rachel O. Abelman; Laura Spring; Beverly Moy; Phoebe Ryan; Mark N. Melkonyan et al.
Source: check_circle
Crossref

Supplementary Table S2 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer

2024-07-15 | Preprint
DOI: 10.1158/1078-0432.26302806.v1
Contributors: Aditya Bardia; Sheng Sun; Nayana Thimmiah; James T. Coates; Bogang Wu; Rachel O. Abelman; Laura Spring; Beverly Moy; Phoebe Ryan; Mark N. Melkonyan et al.
Source: check_circle
Crossref

Supplementary Table S3 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer

2024-07-15 | Preprint
DOI: 10.1158/1078-0432.26302803.v1
Contributors: Aditya Bardia; Sheng Sun; Nayana Thimmiah; James T. Coates; Bogang Wu; Rachel O. Abelman; Laura Spring; Beverly Moy; Phoebe Ryan; Mark N. Melkonyan et al.
Source: check_circle
Crossref

Supplementary Table S3 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer

2024-07-15 | Preprint
DOI: 10.1158/1078-0432.26302803
Contributors: Aditya Bardia; Sheng Sun; Nayana Thimmiah; James T. Coates; Bogang Wu; Rachel O. Abelman; Laura Spring; Beverly Moy; Phoebe Ryan; Mark N. Melkonyan et al.
Source: check_circle
Crossref

Supplementary Table S4 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer

2024-07-15 | Preprint
DOI: 10.1158/1078-0432.26302800
Contributors: Aditya Bardia; Sheng Sun; Nayana Thimmiah; James T. Coates; Bogang Wu; Rachel O. Abelman; Laura Spring; Beverly Moy; Phoebe Ryan; Mark N. Melkonyan et al.
Source: check_circle
Crossref

Supplementary Table S4 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer

2024-07-15 | Preprint
DOI: 10.1158/1078-0432.26302800.v1
Contributors: Aditya Bardia; Sheng Sun; Nayana Thimmiah; James T. Coates; Bogang Wu; Rachel O. Abelman; Laura Spring; Beverly Moy; Phoebe Ryan; Mark N. Melkonyan et al.
Source: check_circle
Crossref

Supplementary Table S5 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer

2024-07-15 | Preprint
DOI: 10.1158/1078-0432.26302797
Contributors: Aditya Bardia; Sheng Sun; Nayana Thimmiah; James T. Coates; Bogang Wu; Rachel O. Abelman; Laura Spring; Beverly Moy; Phoebe Ryan; Mark N. Melkonyan et al.
Source: check_circle
Crossref

Supplementary Table S5 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer

2024-07-15 | Preprint
DOI: 10.1158/1078-0432.26302797.v1
Contributors: Aditya Bardia; Sheng Sun; Nayana Thimmiah; James T. Coates; Bogang Wu; Rachel O. Abelman; Laura Spring; Beverly Moy; Phoebe Ryan; Mark N. Melkonyan et al.
Source: check_circle
Crossref

Supplementary Table S6 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer

2024-07-15 | Preprint
DOI: 10.1158/1078-0432.26302794
Contributors: Aditya Bardia; Sheng Sun; Nayana Thimmiah; James T. Coates; Bogang Wu; Rachel O. Abelman; Laura Spring; Beverly Moy; Phoebe Ryan; Mark N. Melkonyan et al.
Source: check_circle
Crossref

Supplementary Table S6 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer

2024-07-15 | Preprint
DOI: 10.1158/1078-0432.26302794.v1
Contributors: Aditya Bardia; Sheng Sun; Nayana Thimmiah; James T. Coates; Bogang Wu; Rachel O. Abelman; Laura Spring; Beverly Moy; Phoebe Ryan; Mark N. Melkonyan et al.
Source: check_circle
Crossref

Supplementary Table S7 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer

2024-07-15 | Preprint
DOI: 10.1158/1078-0432.26302791.v1
Contributors: Aditya Bardia; Sheng Sun; Nayana Thimmiah; James T. Coates; Bogang Wu; Rachel O. Abelman; Laura Spring; Beverly Moy; Phoebe Ryan; Mark N. Melkonyan et al.
Source: check_circle
Crossref

Supplementary Table S7 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer

2024-07-15 | Preprint
DOI: 10.1158/1078-0432.26302791
Contributors: Aditya Bardia; Sheng Sun; Nayana Thimmiah; James T. Coates; Bogang Wu; Rachel O. Abelman; Laura Spring; Beverly Moy; Phoebe Ryan; Mark N. Melkonyan et al.
Source: check_circle
Crossref
How many people are using ORCID?